Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.

Takara K, Yamamoto K, Matsubara M, Minegaki T, Takahashi M, Yokoyama T, Okumura K.

PLoS One. 2012;7(2):e30697. doi: 10.1371/journal.pone.0030697. Epub 2012 Feb 15.

2.

Differential effects of calcium antagonists on ABCG2/BCRP-mediated drug resistance and transport in SN-38-resistant HeLa cells.

Takara K, Matsubara M, Yamamoto K, Minegaki T, Takegami S, Takahashi M, Yokoyama T, Okumura K.

Mol Med Rep. 2012 Mar;5(3):603-9. doi: 10.3892/mmr.2011.734. Epub 2011 Dec 22.

PMID:
22200670
3.

[Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].

Zhang YH, Li G, Yu J, Xu MS, Liu ZX.

Zhonghua Zhong Liu Za Zhi. 2011 Sep;33(9):654-60. Chinese.

PMID:
22340044
4.

Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.

Ji N, Yuan J, Liu J, Tian S.

Acta Biochim Biophys Sin (Shanghai). 2010 Dec;42(12):854-62. doi: 10.1093/abbs/gmq097.

PMID:
21106767
5.

Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.

Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.

Int J Cancer. 2004 Jan 1;108(1):146-51.

6.

The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.

Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K.

Clin Cancer Res. 2002 Jan;8(1):22-8.

7.

Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.

Zhang Y, Wang H, Wei L, Li G, Yu J, Gao Y, Gao P, Zhang X, Wei F, Yin D, Zhou G.

Breast Cancer Res Treat. 2010 Oct;123(3):679-89. doi: 10.1007/s10549-009-0660-2. Epub 2009 Dec 6.

PMID:
19967559
8.

Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW.

Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499. Erratum in: Cancer Res. 2008 Dec 15;68(24):10387.

9.

Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.

Ee PL, He X, Ross DD, Beck WT.

Mol Cancer Ther. 2004 Dec;3(12):1577-83.

10.

MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.

Zhang F, Throm SL, Murley LL, Miller LA, Steven Zatechka D Jr, Kiplin Guy R, Kennedy R, Stewart CF.

Biochem Pharmacol. 2011 Jul 1;82(1):24-34. doi: 10.1016/j.bcp.2011.03.024. Epub 2011 Apr 1.

11.

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS.

Cancer Res. 2007 Nov 15;67(22):11012-20.

12.

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.

Cancer Res. 2005 Feb 15;65(4):1541-6.

13.

OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.

Kuang YH, Patel JP, Sodani K, Wu CP, Liao LQ, Patel A, Tiwari AK, Dai CL, Chen X, Fu LW, Ambudkar SV, Korlipara VL, Chen ZS.

Biochem Pharmacol. 2012 Sep 15;84(6):766-74. doi: 10.1016/j.bcp.2012.06.019. Epub 2012 Jun 28.

14.

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.

Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.

PMID:
19232821
16.

Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.

Darby RA, Unsworth A, Knapp S, Kerr ID, Callaghan R.

Cancer Chemother Pharmacol. 2015 Oct;76(4):853-64. doi: 10.1007/s00280-015-2858-9. Epub 2015 Sep 9.

PMID:
26351135
17.

Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.

Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F.

Clin Exp Pharmacol Physiol. 2006 Jan-Feb;33(1-2):58-65.

PMID:
16445700
18.

Expression and functional analyses of breast cancer resistance protein in lung cancer.

Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S.

Clin Cancer Res. 2003 Aug 1;9(8):3052-7.

19.

MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).

Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai XF, Yu ZJ, Wu HZ, Sun ML, Song ZG, Wei MJ.

Cancer Lett. 2013 Oct 1;339(1):107-15. doi: 10.1016/j.canlet.2013.07.016. Epub 2013 Jul 20.

PMID:
23879965
20.

Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.

Sun YL, Kathawala RJ, Singh S, Zheng K, Talele TT, Jiang WQ, Chen ZS.

Anticancer Drugs. 2012 Sep;23(8):865-73. doi: 10.1097/CAD.0b013e328354a196.

PMID:
22614107

Supplemental Content

Support Center